• Mon news: AZ obesity pill. 50% of drug shortages last at least 2 years. Pharmas and IRA lawsuit appeals. Novo-Ascendis biobucks deal. Wegovy reduces all-cause hospital admissions. See more on our front page

Celgene's 4th quarter 2017 sales and profit beat estimates











http://alph.st/ba1df6ff Higher sales of Revlimid and Otezla help Celgene to report better than expected sales figure. Will the two (Impact and Juno) multi-billion dollar acquisitions help the struggling Celgene in 2018 and beyond?
struggling Celgene. Yea, continued double digit growth. Problem was, not big enough double digit growth! Not sure if “struggling is the right term. Performance in q3 was under expectations . Maybe time for a “come back”! Glad I’m here !